TD Asset Management
CLDX icon

TD Asset Management’s Celldex Therapeutics CLDX Stock Holding History

TD Asset Management’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.95M Buy
79,326
+9,034
+13% +$292K ﹤0.01% 904
2026
Q1 		$2.23M Buy
70,292
+3,722
+6% +$101K ﹤0.01% 942
2025
Q4 		$1.81M Sell
66,570
-25,880
-28% -$682K ﹤0.01% 1008
2025
Q3 		$2.39M Sell
92,450
-35,428
-28% -$821K ﹤0.01% 929
2025
Q2 		$2.6M Buy
127,878
+49,000
+62% +$954K ﹤0.01% 879
2025
Q1 		$1.43M Sell
78,878
-65,000
-45% -$1.45M ﹤0.01% 1028
2024
Q4 		$3.64M Sell
143,878
-20,200
-12% -$549K ﹤0.01% 851
2024
Q3 		$5.45M Sell
164,078
-25,600
-13% -$975K ﹤0.01% 777
2024
Q2 		$7.02M Sell
189,678
-35,800
-16% -$1.35M 0.01% 683
2024
Q1 		$9.46M Buy
225,478
+173,156
+331% +$7.11M 0.01% 636
2023
Q4 		$2.08M Sell
52,322
-12,600
-19% -$371K ﹤0.01% 995
2023
Q3 		$1.79M Buy
64,922
+32,461
+100% +$1.02M ﹤0.01% 989
2023
Q2 		$1.1M Sell
32,461
-13,300
-29% -$448K ﹤0.01% 1107
2023
Q1 		$1.65M Sell
45,761
-9,500
-17% -$410K ﹤0.01% 1029
2022
Q4 		$2.46M Buy
55,261
+7,600
+16% +$271K ﹤0.01% 926
2022
Q3 		$1.35M Buy
47,661
+11,000
+30% +$337K ﹤0.01% 1108
2022
Q2 		$988K Sell
36,661
-37,168
-50% -$1.08M ﹤0.01% 1182
2022
Q1 		$2.52M Buy
73,829
+11,500
+18% +$368K ﹤0.01% 1015
2021
Q4 		$2.41M Hold
62,329
– – ﹤0.01% 1092
2021
Q3 		$3.37M Buy
62,329
+17,400
+39% +$816K ﹤0.01% 934
2021
Q2 		$1.97M Buy
44,929
+22,079
+97% +$606K ﹤0.01% 1103
2021
Q1 		$471K Buy
22,850
+6,450
+39% +$148K ﹤0.01% 1407
2020
Q4 		$287K Buy
+16,400
New +$295K ﹤0.01% 1389

Other funds holding CLDX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

TD Asset Management's CLDX Position: Q2 2026 in Review

TD Asset Management increased its Celldex Therapeutics (CLDX) stake by 13% in Q2 2026, buying an estimated $292K and bringing the position to 79,326 shares worth $2.95M. The position accounts for ﹤0.01% of the portfolio, ranked #904.

TD Asset Management first reported a position in CLDX in Q4 2020 and has held it in 23 quarters since. The position peaked at $9.46M in Q1 2024. 152 funds tracked by Wall St. Rank hold CLDX as of Q2 2026.

  • TD Asset Management held 79,326 shares of Celldex Therapeutics worth $2.95M as of Q2 2026.
  • TD Asset Management bought 9,034 Celldex Therapeutics shares in Q2 2026, an estimated $292K.
  • Celldex Therapeutics made up ﹤0.01% of TD Asset Management's portfolio in Q2 2026, its #904 holding.
  • TD Asset Management first reported a position in Celldex Therapeutics in Q4 2020 and has held it in 23 quarters since.
  • TD Asset Management's Celldex Therapeutics position peaked at $9.46M in Q1 2024.
  • 152 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2026.

Based on TD Asset Management's 13F filing for Q2 2026, filed 4 Aug 2026.